Cite
HARVARD Citation
Harrison, C. et al. (2022). Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts. British journal of haematology. pp. 317-327. [Online].